Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety Study of Long-Acting Local Anesthetic

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2013 by Children's Hospital Boston
Sponsor:
Information provided by (Responsible Party):
Children's Hospital Boston
ClinicalTrials.gov Identifier:
NCT01786655
First received: February 6, 2013
Last updated: May 21, 2013
Last verified: May 2013
  Purpose

The primary aim of this Phase 1 study is to evaluate the safety of a new prolonged-duration local anesthetic (numbing agent), neosaxitoxin (NeoSTX). The investigators hypothesize that a "minimal adverse effect threshold" NeoSTX dose for subcutaneous administration, in saline and in bupivacaine 0.2% respectively, can be defined for awake, young adult healthy volunteer subjects. At the same time, the pharmacokinetics of the NeoSTX when delivered subcutaneously will be determined.


Condition Intervention Phase
Safety of Neosaxitoxin in Healthy Adult Male Volunteers
Drug: Neosaxitoxin (NeoSTX) in saline
Drug: NeoSTX with 0.2% bupivacaine
Other: Placebo
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Neosaxitoxin (NeoSTX) Alone and in Combination With Bupivacaine as Prolonged Duration Local Anesthetics: A Phase I Investigator-initiated Dose Escalation Study

Resource links provided by NLM:


Further study details as provided by Children's Hospital Boston:

Primary Outcome Measures:
  • Presence or absence of Adverse Events as a function of NeoSTX dose [ Time Frame: Within 14 days of injection ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetic parameters characterizing uptake and distribution of NeoSTX (content in serum and urine samples) [ Time Frame: Within 24 hours of injection ] [ Designated as safety issue: Yes ]
  • Cutaneous sensory blockade (numbness) [ Time Frame: Within 14 days of injection ] [ Designated as safety issue: Yes ]
    measured by noninvasive quantitative sensory testing (QST)

  • Local skin reactions (edema, paresthesias and urticaria) [ Time Frame: Within 14 days of injection ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 77
Study Start Date: May 2013
Estimated Study Completion Date: October 2013
Estimated Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Neosaxitoxin in saline
Subjects receive one injection of NeoSTX in saline on the back of one calf (test side). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 15 mcg, 30 mcg, 45 mcg, 60 mcg, 70 mcg of NeoSTX.
Drug: Neosaxitoxin (NeoSTX) in saline
NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive NeoSTX in saline. Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 15 mcg, 30 mcg, 45 mcg, 60 mcg, 70 mcg of NeoSTX.
Experimental: Neosaxitoxin + bupivacaine 0.2%
Subjects receive one injection of NeoSTX in combination with 0.2% bupivacaine on the back of one calf (test side). Subjects receive NeoSTX with 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 15 mcg, 30 mcg, 45 mcg, 60 mcg, 70 mcg of NeoSTX.
Drug: NeoSTX with 0.2% bupivacaine
NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX with 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 15 mcg, 30 mcg, 45 mcg, 60 mcg, 70 mcg of NeoSTX.
Placebo Comparator: Saline placebo
Subjects receive one injection of saline on the back of one calf (test side).
Other: Placebo
Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy adult males ages 18-35
  2. ASA physical status 1 or 2
  3. English or Spanish speakers
  4. Must be able to come to Boston Children's Hospital for a 24-hour stay and able and willing to attend 5-10 study visits
  5. Must be able to provide informed consent
  6. Must be able to understand and perform all the procedures of the study including self-reporting of symptom scores

Exclusion Criteria:

  1. ASA physical status 3 or greater
  2. Cognitively challenged or other inability to understand the self-report measures or to give informed consent
  3. Significant cardiovascular, respiratory, neuromuscular disease or other systemic illness(es)
  4. No known or suspected allergies to neosaxitoxin, bupivacaine, or other local anesthetics
  5. Subjects may not be on any pain controlling medications, or any medications that would alter pain tolerance
  6. Subjects may not be on any medication that would alter cognition
  7. Subjects may not have any acute or chronic pain conditions requiring ongoing treatment or limiting daily activities
  8. No alcohol or illicit drug abuse
  9. No current smokers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01786655

Contacts
Contact: Joseph Cravero, MD 617-355-7737
Contact: Kimberly Lobo, MPH 857-218-3556 kimberly.lobo@childrens.harvard.edu

Locations
United States, Massachusetts
Boston Children's Hospital Recruiting
Boston, Massachusetts, United States, 02115
Principal Investigator: Joseph Cravero, MD         
Sponsors and Collaborators
Children's Hospital Boston
Investigators
Principal Investigator: Joseph Cravero, MD Children's Hospital Boston
  More Information

No publications provided

Responsible Party: Children's Hospital Boston
ClinicalTrials.gov Identifier: NCT01786655     History of Changes
Other Study ID Numbers: IRB-P00003344
Study First Received: February 6, 2013
Last Updated: May 21, 2013
Health Authority: United States: Food and Drug Administration

Keywords provided by Children's Hospital Boston:
local anesthetic
neosaxitoxin
neoSTX
bupivacaine
safety
phase 1
pharmacokinetic

Additional relevant MeSH terms:
Anesthetics
Anesthetics, Local
Bupivacaine
Neosaxitoxin
Central Nervous System Agents
Central Nervous System Depressants
Neuromuscular Agents
Neuromuscular Blocking Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014